The pathogenesis of a wide range of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases, has been linked to tumor necrosis factor (TNF), a key mediator of apoptosis as well as inflammation and immunity.
TNF- α is a homotrimer in solution and a 17-kDa protein with 157 amino acids. The gene is located on chromosome 6 in humans. Its soluble TNF-binding receptors play a major role in controlling its bioactivity. T lymphocytes, natural killer cells, and activated macrophages are the main producers of TNF-α. Numerous other cells, such as fibroblasts, smooth muscle cells, and tumor cells, are known to have lower expression. TNF- is produced in cells as pro-TNF (26 kDa), which is membrane-bound and is released after TNF-converting enzyme (TACE) cleaves its pro domain.
The two TNF receptors, TNF-R1 and TNF-R2, which are both members of the TNF receptor super-family, mediate many of the cellular responses brought on by TNF. Most cell types respond to TNF treatment by activating the transcription factor NF-B and MAP kinases like ERK, p38, and JNK. In some cases, apoptosis or necrosis may also be induced. However, TNFR1, also referred to as a death receptor, is primarily responsible for the induction of apoptosis or necrosis. Numerous cytokines and immune-regulatory proteins are induced as a result of NF-B and MAPK activation, which is crucial for many inflammatory responses.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V79908 | NLRP3-IN-24 | NLRP3-IN-24 (compound 15a) is an inhibitor (blocker/antagonist) of NLRP3. | |
|
V4039 | Roquinimex | 84088-42-6 | Roquinimex (also known as LS 2616 and FCF89; trade name: Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. |
|
V81596 | TNF-alpha-IN-1 | TNF-alpha-IN-1 (compound 202) is an orally bioactive TNF-alpha inhibitor. | |
|
V76405 | TNF-α (31-45), human TFA | TNF-α (31-45), human TFA is a polypeptide fragment of human tumor necrosis factor-α. | |
|
V76404 | TNF-α (46-65), human TFA | TNF-α (46-65), human (TFA) is a polypeptide fragment of human TNF-α. | |
|
V79140 | TNF-α-IN-11 | TNF-α-IN-11 (Compound 10) is a TNF-α inhibitor (antagonist) with a Kd of 12.06 μM. | |
|
V76007 | TNF-α-IN-2 | 2074702-04-6 | TNF-α-IN-2 is a potent and orally bioactive tumor necrosis factor α (TNFα) inhibitor (antagonist) with IC50 of 25 nM in the HTRF assay. |
|
V76008 | TNF-α-IN-6 | 2699704-20-4 | TNF-α-IN-6 is an orally bioavailable allosteric inhibitor of TNFα (KD = 6.8 nM). |
|
V51738 | TNF-α-IN-9 | 2054199-25-4 | NDM-1 inhibitor-3 |
|
V76010 | UCB-6876 | 637324-45-9 | UCB-6876 is a TNFα inhibitor that binds to the asymmetric crystalline form of the TNF trimer (KD?=?22 μM). |
|
V1944 | VGX-1027 (GIT 27) | 6501-72-0 | VGX-1027 (also known as VGX1027; GIT-27)is an orally bioactive,isoxazoline compound with potent immunomodulatory properties by inhibiting the toll-like receptor 4 (TLR4) signaling pathway. |
|
V74764 | Vonsetamig | 2408319-33-3 | Vonsetamig is a humanized immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E monoclonal antibody (mAb). |
|
V76009 | Zigakibart (Zigakibart; BION-1301) | 2642175-46-8 | Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody (mAb). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
